The Biology and clinical applications of interleukin-2

著者

書誌事項

The Biology and clinical applications of interleukin-2

edited by Robert C. Rees

IRL Press at Oxford University Press, c1990

大学図書館所蔵 件 / 全2件

この図書・雑誌をさがす

注記

Proceedings of an international symposium held at the Octagon Centre, the University of Sheffield, in October 1989; sponsored by the Yorkshire Cancer Research Campaign and the British Society for Immunology

Includes bibliographical references and index

内容説明・目次

内容説明

This publication presents the proceedings of the international symposium held at the University of Sheffield in 1989. It provides an up-to-date account of many important aspects of interleukin-2 (IL-2), and its clinical application. The molecular structure of IL-2 and its receptor subunits provide a basis for understanding lymphocyte activation by IL-2 and the generation of effector cells capable of mediating cytotoxicity towards tumours. Researchers of international standing present authoritative views on the molecular aspects of cell signalling, allowing speculation of the in vivo pathways of activation likely to be important in determining clinical responses. Attention has focussed on the use of cytokines, particularly IL-2, for the treatment of cancer. The recent results from clinical trials using IL-2 and adoptive cellular therapy provide a clear account of the clinical progress, and of the problems encountered in attempting to improve the therapeutic benefit of IL-2. The importance of mechanisms which subverse IL-2 responses is also given.

目次

  • B. Altrock, W.C. Kenney, T. Boone, & P. Hunt: Molecular structure and biology of interleukin-2
  • G. Ju, K. Sauve, P. Bailon, W.-H. Tsien, P. Lin, J. Hakimi, & V. Toome : Structure-activity relationships of human IL-2: identification of residues that bind the IL-2 receptor
  • T. Diamanstein: Interleukin-2 and the interleukin-2 receptor complex
  • J. Ortaldo: Lymphokine-activated killer cells: regulation of activity
  • N.A. Mitchison: IL-2 as a short range physiological mediator
  • F. Triebel & T. Hercend: A reconciled view of the non-MHC requiring cytotoxicity phenomenon
  • K. Karre: Specificities involved in recognition of tumour target cells by IL-2 activated NK cells and T cells: "one receptor" versus "multiple choice" models
  • J.C. Hiserdot: Adherent lymphokine-activated killer cells (A-LAK cells): anti-tumour activity in vitro and in vivo
  • J. Graves, S. Lucas, & D. Cantrell: The regulation of protein kinase C in T Lymphocytes
  • R.H. Wiltrout, H. Futami, H.A. Young, R.L. Hurnung, & T.J. Sayers: Involvement of cytokines in combined modality preclinical approaches to cancer treatment
  • S.P. Creekmore, D.L. Longo, & W.J. Urba: The development of regimens for combination immunotherapy
  • R.B. Herberman, P. Basse, R. Jain, R.J. Melder, R.H. Goldfarb, E. Gorelik, M.S. Ernstoff, J.M. Kirkwood, & T.L. Whiteside: Approaches to immunotherapy with defined populations of IL-2 cultured NK cells, immune T cells, or tumour infiltrating lymphocytes
  • J. Yannelli, J. Maleckar, W. West, & R. Oldham: Cellular biotherapy of cancer: generation, characterization, and use of anti-tumour effector cells
  • J.T. Rubin, S.A. Rosenberg, & M.T. Lotze: The efficacy of high dose recombinant interleukin-2 based immunotherapy in man
  • P.A. Palmer & C.R. Franks: Prospects of IL-2 in cancer therapy
  • P.J. Guillou: Tumour escape mechanisms
  • G. Gallagher & P.J. Guillou: Open paper and poster sections.

「Nielsen BookData」 より

詳細情報

ページトップへ